CTMX लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (1 Jun 2024 @ 01:30):

Stats
आज की मात्रा	950 258
औसत मात्रा	6.45M
बाजार मूल्य	132.46M
EPS	$0 ( 2024-05-14 )
अगली कमाई की तारीख	( $0 ) 2024-08-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	8.10
ATR14	$0.00400 (0.24%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-15	Young Matthew P.	Buy	38 000	Stock Option (Right to Buy)
2024-05-15	Su Zhen	Buy	38 000	Stock Option (Right to Buy)
2024-05-15	Mohindru Mani	Buy	38 000	Stock Option (Right to Buy)
2024-05-15	Meyers James R	Buy	38 000	Stock Option (Right to Buy)
2024-05-15	Jones Elaine V	Buy	38 000	Stock Option (Right to Buy)

INSIDER POWER
67.38
Last 98 transactions
Buy: 4 955 428 \| Sell: 1 092 240

मात्रा सहसंबंध

लंबा: -0.54 (weak negative)

छोटा: -0.47 (neutral)

Signal:(18.208) Neutral

CytomX Therapeutics Inc सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध
OZEM	1
LOGC	0.91
NALFX	0.894
BWIN	0.893
IIXIX	0.892
RGSVX	0.888
RGIVX	0.888
ANTUX	0.887
PGJZX	0.883
INFR	0.879

10 सबसे अधिक नकारात्मक सहसंबंध
PLTNU	-0.886
LDWY	-0.847
AAPD	-0.83
BRLSW	-0.828
CGON	-0.818
PXMD	-0.812

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

CytomX Therapeutics Inc सहसंबंध - मुद्रा/वस्त्र

0.78
( moderate )

0.76
( moderate )

0.00
( neutral )

-0.64
( weak negative )

CytomX Therapeutics Inc वित्तीय

Annual	2023
राजस्व:	$101.21M
सकल लाभ:	$99.04M (97.85 %)
EPS:	$-0.00770

FY	2023
राजस्व:	$101.21M
सकल लाभ:	$99.04M (97.85 %)
EPS:	$-0.00770

FY	2022
राजस्व:	$53.16M
सकल लाभ:	$47.31M (88.98 %)
EPS:	$-1.480

FY	2021
राजस्व:	$69.57M
सकल लाभ:	$69.57M (100.00 %)
EPS:	$-1.300

Financial Reports:

Symbol	Period	Year	Title
CTMX	Q1	2024	Q1 2024 Financial Performance Analysis of CytomX Therapeutics Inc.

CytomX Therapeutics Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

CytomX Therapeutics Inc

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.